ETFsRussell 1000 Growth Net
Amundi
Amundi Russell 1000 Growth UCITS ETF Acc
MWOT XETRAAccumulatingPhysical, full replicationIrelandNot PEA-eligible
Last close · EUR
505.61EUR
-4.78% · -€25.36
Published closes: 4 Nov 2026 - 5 Nov 2026
5 Nov 2026, close
MWOTBase
- Fund charges
- 0.19%Total expense ratio (TER)
- Fund size
- €582.5Mall share classes
- Return 1Y
- -4.0%
- Sharpe 3Y
- Not published
- Volatility 1Y
- 17.6%annualised
- Holdings
- 361Fund holdings
Performance
Compare
- MWOT-4.0%
- Price, EUR
Returns
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|
| MWOT | -12.0% | -6.9% | -2.3% | -0.8% | -4.0% | - | - |
| MSCI World | -2.8% | -0.6% | +7.8% | +14.0% | +14.1% | +65.6% | +64.8% |
| Gap to MSCI World | -9.1% | -6.3% | -10.1% | -14.8% | -18.1% | - | - |
Risk and return
Sharpe ratio · 1Y
-0.04
Below MSCI World · 1.28- Return p.a.
- -0.2%
- Volatility
- 17.6%
- Max loss
- -14.7%Mar 2026
Sharpe vs indices
MSCI World
1.28
S&P 500
1.16
STOXX Europe 600
0.99
MSCI Emerging Markets IMI
0.76
CAC 40
-0.01
MWOT
-0.04
Method
Weekly EUR returns from adjusted closes. Sharpe is the annualised excess return over the euro overnight rate (Xtrackers II EUR Overnight Rate Swap UCITS ETF 1C) divided by its volatility. Max loss uses daily closes.
Top holdings
- Top 10
- 56.9%
- Holdings
- 361
- As of
- 1NVIDIA CORPUS67066G104014.50%
- 2APPLE INCUS03783310058.51%
- 3MICROSOFT CORPUS59491810456.42%
- 4ALPHABET INC CL AUS02079K30595.23%
- 5BROADCOM INCUS11135F10124.71%
- 6ALPHABET INC CL CUS02079K10794.25%
- 7META PLATFORMS INC-CLASS AUS30303M10273.52%
- 8ELI LILLY & COUS53245710833.52%
- 9TESLA INCUS88160R10143.50%
- 10MICRON TECHNOLOGY INCUS59511210382.79%
Countries
Classified 99.6%
United States99.6%
- Largest
- 99.6%United States
- Top 3
- 99.6%
- Effective number
- 1.01 / HHI
Market cap
Weight vs holdings
56.9%of the fund sits in the top 10 holdings
56.9%26.8%13.9%
WeightHoldings
40150161
- Holdings 1-10
- Holdings 11-50
- Holdings 51-200
- Holdings 201+
Size split
Not published
Compare ETFs in Copio.
Factual research, without a suitability score or investment recommendation. Past relationships can change.
